Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex
Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex
复制标题
艾滋病和晚期艾滋病相关综合症患者的长期齐多夫定治疗
DOI：
10.1001/jama.1989.03430170067030
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
D. Barry
中科院分区：
文献类型：
--
作者：
M. Fischl;Richman Dd;D. Causey;M. Grieco;Y. Bryson;D. Mildvan;O. Laskin;J. Groopman;P. Volberding;R. Schooley;G. Jackson;D. Durack;J. Andrews;S. Nusinoff;D. Barry
我们对229例曾参加过齐多夫定安慰剂对照研究的艾滋病相关综合征患者进行了齐多夫定治疗的长期安全性和有效性研究。102名安慰剂接受者（延迟治疗组）和127名齐多夫定接受者（初始治疗组）在接受齐多夫定治疗期间进行了平均21个月的随访。初始治疗组12个月和21个月的生存率分别为84.5%和57.6%，延迟治疗组12个月和18个月的生存率分别为78.8%和64.6%;原治疗组中77例AIDS受试者在12个月和21个月时的有效率分别为78.8%和47.5%，50例AIDS相关综合征受试者分别为93.0%和71.8%。不良反应随着时间的推移而减少，新观察到的毒性反应不常见。这些受试者的临床过程表明长期齐多夫定治疗可持续生存获益。（JAMA . 1989;262：2405-2410）
We examined the long-term safety and efficacy of zidovudine therapy in 229 subjects with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex who previously participated in a placebo-controlled study of zidovudine. One hundred two placebo recipients (delayed treatment group) and 127 zidovudine recipients (original treatment group) were followed up while receiving zidovudine therapy for a mean of 21 months. Survival rates for the original treatment group were 84.5% and 57.6% at 12 and 21 months, respectively; for the delayed treatment group, 78.8% and 64.6% at 12 and 18 months, respectively; and 78.8% and 47.5% at 12 and 21 months, respectively, for 77 subjects with AIDS and 93.0% and 71.8%, respectively, for 50 subjects with AIDS-related complex in the original treatment group. Adverse reactions decreased over time and newly observed toxic reactions were unusual. The clinical course of these subjects suggests continued survival benefits with long-term zidovudine therapy. ( JAMA . 1989;262:2405-2410)
影响因子：
56.9
作者：
LARDER, BA;DARBY, G;RICHMAN, DD
通讯作者：
RICHMAN, DD